Quantum biopharma announces the record date for the distribution of a special dividend of contingent value rights (cvrs) tied to the future litigation settlement proceeds of its usd $700 million+ case

Toronto, oct. 03, 2025 (globe newswire) -- quantum biopharma ltd. (nasdaq: qntm) (cse: qntm) (fra: 0k91) (“quantum biopharma” or the “company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its board of directors has established october 27, 2025 as the record date for the distribution of contingent value rights (“cvrs”) to holders of its class b subordinate voting shares on a one-for-one basis, advancing the company's previously disclosed plan in the company's press release dated june 13, 2025, to deliver a litigation-linked cvr to shareholders of record as of the record date.
QNTM Ratings Summary
QNTM Quant Ranking